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Abstract
Emerging evidence suggests that RANKL-induced changes in chromatin state are important for 
osteoclastogenesis, but these epigenetic mechanisms are not well understood and have not been 
therapeutically targeted. In this study we find that the small molecule I-BET151 that targets bromo 
and extra-terminal (BET) proteins that “read” chromatin states by binding to acetylated histones 
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strongly suppresses osteoclastogenesis. I-BET151 suppresses pathologic bone loss in TNF-
induced inflammatory osteolysis, inflammatory arthritis, and post-ovariectomy models. 
Transcriptome analysis identifies a MYC-NFAT axis important for osteoclastogenesis. 
Mechanistically, I-BET151 inhibits expression of the master osteoclast regulator NFATC1 by 
suppressing expression and recruitment of its newly identified upstream regulator MYC. MYC is 
elevated in rheumatoid arthritis and its induction by RANKL is important for osteoclastogenesis 
and TNF-induced bone resorption. These findings highlight the importance of an I-BET151-
inhibited MYC-NFAT axis in osteoclastogenesis, and suggest targeting epigenetic chromatin 
regulators holds promise for treatment of inflammatory and estrogen deficiency-mediated 
pathologic bone resorption.
Introduction
Osteoclasts are bone-resorbing cells important for bone homeostasis and pathological bone 
resorption 1–5. M-CSF and RANKL are key factors required for differentiation of myeloid 
lineage cells into osteoclasts. M-CSF promotes proliferation and survival of myeloid cells 
and induces expression of RANK, the receptor for the key inducer of osteoclastogenesis 
RANK ligand (RANKL). RANKL drives osteoclast differentiation by activating NF-κB, 
MAPK and calcium signaling pathways to induce and activate transcription factor NFATc1, 
a master regulator of osteoclastogenesis. RANKL-mediated signaling pathways are well 
characterized 1 and RANKL-RANK interactions and downstream signaling pathways have 
been targeted to treat osteoporosis and other bone diseases. Recently, it has become apparent 
that RANKL-induced changes in chromatin state of osteoclast precursors are important for 
osteoclastogenesis 6,7. However, epigenetic mechanisms that regulate osteoclast 
differentiation have not been well clarified or therapeutically targeted.
Epigenetic regulation, which includes modifications of DNA and chromatin, and expression 
of noncoding RNA, plays an important role in physiological responses and pathological 
conditions 8–10. Recent development of drugs that target epigenetic mechanisms, including 
chromatin states, holds great promise in treating diseases such as cancers 11,12. 
Bromodomain and extra-terminal (BET) proteins “read” chromatin states by binding to 
acetylated histones (H-Ac) via bromodomains, and recruit additional chromatin regulators to 
control gene transcription 13. Small molecule inhibitors which target the BET family have 
been generated and inhibition of interaction of BET proteins with H-Ac using small 
molecule inhibitors effectively suppresses tumor growth and inflammatory responses in 
mouse models 13–19. These inhibitors show high specificity for their targets, specifically 
binding the BET family proteins, and minimal systemic toxicity, suggesting a high potential 
as effective and safe therapeutics 11,14,15,20. Here, we report that the small molecule 
inhibitor I-BET151 that targets BET proteins effectively suppresses RANKL-induced 
osteoclastogenesis. I-BET151 treatment suppressed in vivo bone loss in post ovariectomy 
osteoporosis, inflammatory arthritis, and TNF-induced osteolysis mouse models. 
Transcriptome analysis revealed that I-BET 151 inhibits NFATc1 expression by suppressing 
MYC, and we identified a MYC-NFAT axis important for osteoclastogenesis that is targeted 
by I-BET151. These findings implicate MYC and BET proteins in osteoclastogenesis, and 
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suggest targeting epigenetic chromatin regulators as a new therapeutic approach for 
controlling inflammatory bone resorption.
Results
I-BET151 suppresses osteoclastogenesis in vitro and in vivo
We tested the effects of BET bromodomain protein inhibition on osteoclast differentiation. 
I-BET151 suppressed the differentiation of human and mouse osteoclast precursors (OCPs) 
into multinucleated tartrate-resistant acid phosphatase (TRAP)-positive cells in a dose-
dependent manner (Fig. 1a and Supplementary Fig. 1a). Accordingly, I-BET151 strongly 
suppressed RANKL-induced expression of osteoclast-related genes such as CTSK (encodes 
cathepsin K) and ITGB3 (encodes β3 integrin) in human and mouse OCPs (Fig. 1b and 
Supplementary Fig. 1b). Reduced osteoclast formation did not result from changes in cell 
viability or number, as assessed by MTT assays (Supplementary Fig. 2a, b). We next tested 
whether I-BET151 could inhibit osteoclastogenesis in vivo. I-BET151 strongly inhibited 
osteoclastogenesis and associated bone erosion in vivo in the TNF-induced supracalvarial 
osteolysis model (Fig. 1c). Consistently, serum TRAP levels were lower in the I-BET151 
treated group compared to the vehicle-treated control group (Fig. 1d). The reduction in in 
vivo osteoclastogenesis was further confirmed using histomorphometric analysis to quantify 
osteoclast numbers and surface area; both osteoclast surface area per bone surface (OcS/BS) 
and osteoclast numbers per bone surface (NOc/BS) were significantly lower in the I-
BET151-treated group (Fig. 1e). Collectively, our results show that I-BET151 suppressed 
osteoclastogenesis in vitro and in vivo.
I-BET151 protects mice from bone loss in OVX and arthritis
To further test the efficacy of inhibiting BET proteins in the treatment of pathological bone 
loss, we examined the effect of I-BET151 on bone loss in post-ovariectomy (OVX) 
osteoporosis using a therapeutic experimental design. I-BET151 treatment was started four 
weeks after OVX and continued for five weeks (Fig. 2a). Microcomputed tomography 
(μCT) analysis revealed that I-BET151 treatment resulted in significantly increased bone 
mass relative to vehicle-treated mice (Fig. 2b, c). Biomechanical properties of the femurs 
were assessed by three-point bending and I-BET151 resulted in significantly increased bone 
strength compared to vehicle treated ovariectomized mice (Fig. 2d). Histomorphometry 
showed that I-BET151 decreased osteoclast numbers and surface area, supporting a 
suppressive effect of I-BET151 on osteoclastogenesis (Fig. 2e). Consistent with previous 
observations 21, the effects of I-BET in the OVX model with a therapeutic design were 
similar to those of alendronate (Supplementary Fig. 3), a well-known anti-resorptive reagent 
that targets osteoclasts with minimal direct effects on osteoblasts22. However, we tested the 
effects of I-BET151 on osteoblast function. At the doses used to suppress osteoclastogenesis 
in vivo, I-BET151 treatment did not significantly affect mineral apposition rate (MAR) and 
bone formation rate (BFR) in ovariectomized mice (Supplementary Fig. 4). However, I-
BET151 suppressed in vitro osteoblast differentiation at concentrations 5-10-fold higher 
than those required to suppress osteoclastogenesis (Supplementary Fig. 5). Thus, our results 
suggest that I-BET151 therapeutically increases bone mass in the OVX model by 
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suppressing osteoclastogenesis, but that supra-therapeutic doses have the potential to 
suppress osteoblast-mediated bone formation.
We next tested the effects of I-BET151 in K/BXN serum-induced arthritis, which models 
the inflammatory effector phase of arthritis and is characterized by joint inflammation and 
associated bone resorption 23. I-BET151-treated mice showed decreased joint swelling and 
inflammation compared to vehicle-treated control mice (Fig. 3a, b and Supplementary Fig. 
6). I-BET151-treated mice also showed decreased serum TRAP and decreased osteoclast 
numbers in periarticular bone (Fig. 3c–e). K/BXN serum-induced arthritis is induced by 
articular immune complexes and is highly dependent on interleukin-1 (IL-1)24 and 
chemokine-mediated recruitment of neutrophils 25. To gain insights into how I-BET151 
inhibits arthritic inflammation, we found that I-BET151 suppresses the induction of IL-1 by 
immune complexes and various inflammatory stimuli, and also attenuates induction of 
neutrophil chemokines by immune complexes or IL-1 (Supplementary Fig. 7). These results 
suggest that in the K/BXN arthritis model, I-BET151 potently suppresses bone resorption by 
a dual action of suppressing inflammation and directly targeting osteoclast differentiation. 
Taken together, our results establish in vivo efficacy of I-BET151 and suggest that inhibition 
of BET proteins may represent an effective therapeutic approach for suppressing bone loss.
I-BET151 suppresses RANKL-induced NFATc1 expression
To test in an unbiased manner for potential targets of I-BET151 that could yield insight into 
its mechanisms of action, we performed a transcriptomic analysis using high throughput 
RNA sequencing (Supplementary Fig. 8). I-BET151 suppressed expression of 465 RANKL-
induced genes by >50% in two independent donors. These genes are depicted in the heat 
map in Fig. 4a and listed in Supplementary Table 1; Supplementary Figs. 9–11 and legends 
describe our analysis of transcriptomic data. Strikingly, of the 465 I-BET151 targets, 120 
genes (26%) are target genes of the master regulator of osteoclastogenesis NFATC126 
(Supplementary Table 2), and expression of NFATC1 itself was suppressed (Fig. 4a). 
NFATc1 drives the early stages of osteoclast differentiation 27–29, NFATc1-deficient mice 
develop severe osteopetrosis in vivo 30, and NFATc1-deficient cells are incapable of 
differentiating into osteoclasts in vitro 28,29,31. Thus, we focused on understanding how I-
BET151 suppresses NFATC1 to downregulate osteoclastogenesis. In both human and mouse 
OCPs, RANKL-induced NFATc1 mRNA and protein expression were inhibited by I-
BET151 in a dose-dependent manner (Fig. 4b, c and Supplementary Fig. 12a, b). I-BET151 
also suppressed RANKL-induced expression of Blimp1, another key regulator of 
osteoclastogenesis that is induced in part by NFATc132,33 (Fig. 4c and Supplementary Fig. 
12a). Downregulation of NFATC1 expression by I-BET151 was not secondary to inhibition 
of upstream RANK signaling (Supplementary Fig. 13a) or induction of known 
transcriptional repressors of NFATC1 and osteoclast differentiation (Supplementary Fig. 
13b), suggesting that I-BET151 either directly targets the NFATC1 locus or suppresses an as 
yet unknown activator of NFATC1.
We next investigated mechanisms by which I-BET151 inhibits NFATC1 expression. I-
BET151 directly inhibits gene expression by disrupting binding of BET proteins to gene 
loci14. However, using chromatin immunoprecipitation (ChIP) assays, we found that 
Park-Min et al. Page 4
Nat Commun. Author manuscript; available in PMC 2015 May 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
RANKL stimulation resulted in only a modest and not statistically significant recruitment of 
BET proteins such as Brd4 to the NFATC1 locus (Fig. 4d). Although suppression of Brd4 
recruitment (Fig. 4d) could contribute to suppression of NFATC1 expression, the weak 
recruitment of Brd4 suggested that I-BET151 could also regulate NFATC1 expression 
indirectly, potentially by suppressing the expression of a transcriptional activator required 
for NFATC1 transcription. Such an indirect mechanism of action was supported by the 
finding that I-BET suppressed RANKL-induced increases in the positive histone mark H4-
Ac at the NFATC1 locus (Fig. 4e), and, concomitantly, RANKL-induced recruitment to 
NFATC1 of CBP, a key histone acetyltransferase (HAT) that mediates histone acetylation 
(Fig. 4f). Decreased recruitment of CBP to the NFATC1 promoter suggests that I-BET151 
may suppress a RANKL-induced transcription factor that is required to recruit HATs to 
acetylate histones at NFATC1.
MYC-NFATc1 axis is important for osteoclast differentiation
Although the currently appreciated important transcriptional regulators of 
osteoclastogenesis34 are not known BET targets (Fig. 4a and Supplementary Fig. 13), the 
transcription factor MYC is dependent on BET proteins 18,35 and was suggested to play a 
role in osteoclastogenesis in RAW267.4 cells and mouse osteoclasts 36,37; however, 
mechanisms by which MYC regulates osteoclastogenesis remain to be elucidated. 
Strikingly, analysis of our transcriptomic data showed that 73 out of 465 (16%) of I-BET 
targets correspond to MYC target genes (Supplementary Fig. 10), that MYC-dependent 
cellular processes were suppressed by I-BET (Supplementary Figs. 9 and 11) and that MYC- 
and NFAT-target genes overlap (Supplementary Fig. 10). These results support the idea that 
a MYC-NFATC1 axis is important for osteoclastogenesis and thus we addressed the role of 
MYC in our system. RANKL induced MYC (Fig. 5a) with similar kinetics as induction of 
NFATc1 (Supplementary Fig. 14). I-BET151 abrogated RANKL-induced MYC expression 
in human and mouse OCPs (Fig. 4a, 5a and Supplementary Fig. 15). To examine the role of 
MYC in human OCPs, we treated cells with MYC inhibitor 10058-F4 38 or knocked down 
MYC expression using siRNAs. Inhibition of MYC suppressed osteoclast differentiation 
(Fig. 5b). We then tested whether MYC regulates the expression of NFATC1. MYC 
inhibitor 10058-F4 inhibited RANKL-induced NFATC1 mRNA and protein expression in 
dose-dependent manner in human and mouse OCPs (Fig. 5c, d and Supplementary Fig. 16). 
Consistently, siRNA-mediated knockdown of MYC inhibited osteoclastogenesis and 
RANKL-induced NFATc1 expression (Supplementary Fig. 17). Furthermore, ChIP assays 
showed that RANKL stimulation induced recruitment of MYC to the NFATC1 promoter, 
supporting direct regulation of NFATC1 by MYC (Fig. 5e). This RANKL-induced 
occupancy of MYC at the NFATC1 promoter was effectively suppressed by I-BET151 (Fig. 
5e). Inhibition of MYC decreased RANKL-induced H4-Ac at the NFATC1 promoter (Fig. 
5f) in a manner parallel to decreased H4-Ac after I-BET151 treatment (Fig. 4e). These 
results indicate that MYC is required for the induction of H4-Ac at the NFATC1 promoter. 
Accordingly, MYC inhibition resulted in similar decreases in RANKL-induced recruitment 
of CBP to NFATC1 (Fig. 5g). These results establish inhibition of MYC as a mechanism by 
which I-BET151 regulates NFATC1, and support a role for MYC in osteoclastogenesis. We 
previously reported that the expression of NFATC1 protein is increased in synovial OCPs of 
rheumatoid arthritis (RA) patients 39, which have a higher potential for differentiating into 
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osteoclasts 40. To investigate a potential role for MYC in vivo, we first examined MYC 
expression in RA synovial OCPs. Quantitative RT-PCR analysis showed significantly 
increased MYC expression in RA synovial CD14+ OCPs relative to disease controls, and a 
parallel increase in NFATC1 mRNA (Fig. 5h). These results suggested a role for MYC in 
osteoclastogenesis in inflammatory settings, which we further investigated using the TNF-
induced supracalvarial osteolysis model. Similar to I-BET151 treatment, the MYC inhibitor 
10058-F4 suppressed TNF-induced serum TRAP (Fig. 5i) and significantly reduced both 
osteoclast surface area per bone surface (OcS/BS) and osteoclast numbers per bone surface 
(NOc/BS) (Fig. 5j). Taken together, these results reveal MYC as an important factor in 
osteoclastogenesis and suggest targeting MYC as a new therapeutic strategy to control bone 
resorption.
Discussion
Cytokines, receptors, signaling pathways and transcription factors that regulate 
osteoclastogenesis have been extensively characterized 1,41, resulting in the identification of 
therapeutic targets, such as RANKL and NFATC1, for the treatment of pathological bone 
resorption 2–4. Emerging evidence suggests that chromatin states and related epigenetic 
mechanisms that control how information encoded in DNA is expressed play an important 
role in osteoclastogenesis 6,7,31. As many chromatin regulators are enzymes or ‘readers’ that 
can be targeted by conventional small molecule approaches 11, this opens up new 
therapeutic opportunities for suppression of osteoclastogenesis and pathologic bone 
resorption. In this study, we show that I-BET151 inhibits osteoclast differentiation and 
suppresses in vivo osteoclastogenesis and pathologic bone resorption in three distinct disease 
models: TNF-induced inflammatory osteolysis, inflammatory arthritis, and post ovariectomy 
low estrogen-mediated osteoporosis. Mechanistically, I-BET151 inhibited expression of the 
master osteoclast regulator NFATC1 by suppressing expression and recruitment of its 
upstream regulator MYC. MYC was elevated in rheumatoid arthritis synovial macrophages 
and its induction by RANKL was important for osteoclastogenesis and TNF-induced bone 
resorption. These results highlight the importance of an I-BET151-inhibited MYC-NFATC1 
axis in osteoclastogenesis and pathologic bone resorption.
Epigenetic mechanisms contribute to regulation of the expression of genes, and therapies 
targeting epigenetic marks including DNA methylation and histone modifications such as 
acetylation and methylation show therapeutic efficacy in several diseases and various 
disease models11,12. In preclinical studies the related compounds I-BET151 and I-BET762, 
and JQ1, appear safe and highly efficacious in treatment of NUT midline carcinoma, acute 
myeloid leukemia, and multiple myeloma 15,18,42 and I-BET76214 is currently in clinical 
trials (clinicaltrials.gov reference NCT01587703). We have demonstrated therapeutic 
efficacy of I-BET151, a compound that targets an epigenetic mechanism important for 
osteoclastogenesis, in increasing bone mass and strength in the standard post OVX model of 
osteoporosis. While our manuscript was under revision, the related BET inhibitor JQ1 was 
reported to suppress osteosarcoma-mediated bone remodeling by suppressing the function of 
both osteoclasts and osteoblasts 43. As we have found that 5-10-fold higher concentrations 
of I-BET151 are required to suppress osteoblast differentiation than osteoclastogenesis 
(Supplementary Figs. 1 and 5), the differences in results, namely the lack of suppression of 
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osteoblast function in vivo in our study, may be explained by differences in dosing or 
pharmacokinetics of these two BET inhibitors. Alternatively, it is possible that distinct 
pathogenic mechanisms in inflammatory or low estrogen-mediated bone loss versus tumor-
mediated bone remodeling5 result in differential responses to BET inhibitors. Overall our 
results in the post-ovariectomy model that I-BET151 suppressed osteoclastogenesis and 
bone resorption but minimally affected bone formation suggest a therapeutic window in 
which I-BET151 can exert beneficial effects on bone mass.
I-BET151 effectively suppressed osteoclastogenesis and pathologic bone resorption in 
inflammatory disease models. Inflammatory bone resorption can be refractory to established 
antiresorptive therapies 3,44, such as bisphosphonates, that target osteoclasts. In the K/BxN 
arthritis model, I-BET151 suppressed inflammation as well as bone resorption. Thus, I-
BET151 offers the advantage of both suppressing inflammation, thus indirectly dampening 
osteoclastogenesis, and directly suppressing osteoclast differentiation. BET inhibitors have 
been shown to suppress induction of inflammatory secondary response genes by bacterial 
lipopolysaccharide (LPS)14 and we have extended this work to show that I-BET151 
suppresses immune complex- and IL-1-induced expression of cytokines and neutrophil 
chemoattractants that are important for inflammatory arthritis. The combined effect of 
suppressing inflammation and osteoclastogenesis suggests targeting BET proteins may be 
effective in suppressing pathological bone resorption that occurs in inflammatory settings.
BET inhibitors may have different therapeutic targets in various diseases11. One such target 
is MYC and BET inhibitors have therapeutic applications in MYC-driven disorders, which 
have otherwise been refractory to various therapeutic strategies to target MYC. Our results 
suggest that in osteoclasts I-BET151 works at least in part by suppressing MYC and 
targeting a newly described MYC-NFAT axis important for osteoclastogenesis. MYC has 
been previously implicated in osteoclastogenesis but the mechanism by which MYC 
regulates osteoclastogenesis was not clear36,37. Our investigation of mechanisms of I-
BET151 action revealed a role for MYC in osteoclast differentiation and inflammatory bone 
resorption. One mechanism of MYC action was direct binding to and activation of NFATC1 
expression, although it is possible that MYC also promotes osteoclastogenesis by additional 
mechanisms that remain to be investigated. In summary, our results on the importance of 
BET proteins and MYC in osteoclastogenesis open new lines of investigation in the 
understanding and therapeutic targeting of pathological bone resorption.
Methods
Mice and analysis of bone phenotype
Six week-old female C57BL/6 were purchased from The Jackson Laboratory (Bar Harbor, 
ME). All animal experiments were approved by the Hospital for Special Surgery 
Institutional Animal Care and Use Committee (IACUC). All animals were randomly 
assigned into experimental groups. For ovariectomy (OVX) -induced bone loss model, 
sixteen week-old sham-operated or ovariectomized CD-1 mice were purchased from Charles 
River Laboratory (Wilmington, MA). I-BET151 was prepared in 10% KLEPTOSE® 
(Roquette Pharma) following the manufacturer’s instructions. Ovariectomized mice were 
randomly divided into two groups (vehicle vs. I-BET; n=12 per group). To analyze the 
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therapeutic effect of I-BET151, either vehicle or I-BET151 (30mg kg−1) was administrated 
intraperitoneally (i.p.) once per day beginning 4 weeks after surgery. I-BET151 or vehicle 
injection was continued for five weeks. After five-week treatment, femurs were isolated and 
micro–computed tomography (μ-CT) analysis45 was performed at the Musculoskeletal 
Repair and Regeneration Core Center in Hospital for Special Surgery as described 
previously 46, and all samples were included in the analysis conducted in a blinded manner. 
For arthritis experiments, K/BxN serum pools were prepared as described previously47. 
Arthritis was induced by intraperitoneal injection of 100 μl of K/BxN serum on days 0 and 
2. Arthritic mice were divided into 2 groups (vehicle vs. I-BET151; n=9 mice per group) and 
were administered vehicle or I-BET151 (40 mg kg−1) once on days 0 and 2 and twice per 
day from day 3 to day 6. Control group (n=9) only received vehicle but not arthritic serum. 
The severity of arthritis was monitored by measuring the thickness of both the wrist and 
ankle joints using dial-type calipers (Bel-Art Products). For each animal, joint thickness was 
calculated as the sum of the measurements of both wrists and both ankles. Joint thickness 
was represented as the average for every treatment group. For inflammatory osteolysis 
experiments, we used an established mouse model, the TNF-induced supracalvarial 
osteolysis model 48 with minor modifications. In brief, TNF was administrated daily at the 
doses indicated in the figure legends to the calvarial periosteum of mice for four to five 
consecutive days. The mice were then sacrificed for the collection of serum and calvarial 
bones for sectioning. For histopathologic assessment, mice were euthanized, and the hind 
paws and calvarial bones were harvested and fixed in 4% paraformaldehyde for 2 days. 
These samples were decalcified with 10% neutral buffered EDTA (Sigma-Aldrich) and 
embedded in paraffin. To assess osteoclastogenesis and bone resorption, sections were 
stained with TRAP (tartrate-resistant acid phosphatase) and hematoxylin for osteoclast 
visualization, and histomorphometric analysis was performed with the BioQuant image 
analysis system (Nashville, TN, USA) using standard procedures 49. Osteoclasts were 
identified as TRAP+ cells that were multinucleated and adjacent to bone. As markers for 
osteoclast formation and bone resorption, serum TRAP5b was measured with the RatLaps 
enzyme immunoassay (EIA) kit (Immunodiagnostic Systems) following the manufacturer’s 
instructions.
Three-point bending test
The whole bone strength of the femur was measured in bending. Femurs were loaded in 
three-point bending to failure50. The bones were positioned with the posterior aspect resting 
on the supports (6 mm span) and the load was applied to the anterior mid-diaphysis at a rate 
of 0.1 mm/s (Bose Enduratec). The bending strength (maximum moment) and stiffness were 
determined from the applied load and displacement data. All samples were included in the 
analysis conducted in a blinded manner.
Reagents
Human and murine M-CSF, sRANKL and TNF were purchased from Peprotech (Rocky 
Hill, NJ). I-BET was synthesized by GlaxoSmithKline (UK) as previously described15,51,52. 
MYC inhibitor 10058-F4 was purchased from Sigma-Aldrich. The MTT assay kit was 
purchased from Roche, and cell viability was measured following the manufacturer’s 
instructions. The antibodies (1:1000) used for immunoblotting are as follows: NFATc1(BD 
Park-Min et al. Page 8
Nat Commun. Author manuscript; available in PMC 2015 May 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Pharmagen; 556602); c-myc and p38 (Santa Cruz Biotechnology; sc-764 and sc535); Lamin 
B (Abcam; ab16048); phospho-ERK, IκBα, phospho-p38 and Blimp1 (Cell Signaling; 9101, 
9242, 9215, 9115).
Cell culture
Peripheral blood mononuclear cells were obtained from blood leukocyte preparations 
purchased from the New York Blood Center by density gradient centrifugation with Ficoll 
(Invitrogen, Carlsbad, CA) using a protocol approved by the Hospital for Special Surgery 
Institutional Review Board. Monocytes were obtained from peripheral blood using anti-
CD14 magnetic beads, as recommended by the manufacturer (Miltenyi Biotec Auburn, CA). 
Monocyte-derived osteoclast precursors (OCPs) that express RANK were obtained by 
culturing for one day with 20 ng ml−1 of M-CSF (Peprotech) in α-MEM medium 
(Invitrogen) supplemented with 10 % fetal bovine serum (FBS, Hyclone), and the purity of 
monocytes was >97%, as verified by flow cytometric analysis.
Osteoclast differentiation
Human CD14+ cells were incubated with 20 ng ml−1 of M-CSF for one day to generate 
OCPs. For human osteoclastogenesis assays, cells were added to 96 well plates in triplicate 
at a seeding density of 5×104 cells per well. Osteoclast precursors were incubated with 20 ng 
ml−1of M-CSF and 40 ng ml−1of human soluble RANKL for five additional days in α-MEM 
supplemented with 10 % FBS. Cytokines were replenished every 3 days. On day 6, cells 
were fixed and stained for TRAP using the Acid Phosphatase Leukocyte diagnostic kit 
(Sigma) as recommended by the manufacturer. Multinucleated (greater than 3 nuclei), 
TRAP-positive osteoclasts were counted in triplicate wells. For mouse osteoclastogenesis, 
bone marrow (BM) cells were flushed from femurs of mice and cultured with murine M-
CSF (20 ng ml−1, Peprotech) on petri dishes in α-MEM supplemented with 10% FBS after 
lysis of RBCs using ACK lysis buffer (Cambrex, Walkersville, MD). Then, the non-
adherent cell population was recovered the next day and cultured with murine M-CSF (20 
ng ml−1) for three additional days. We defined this cell population as mouse OCPs. For 
murine osteoclastogenesis assays, we plated 2×104 OCPs per well in triplicate wells on a 96 
well plate and added M-CSF and RANKL (100 ng ml−1) for an additional 6 days, with 
exchange of fresh media every 3 days. Imaging was performed with a 10X objective.
Gene expression analysis
For real time PCR, DNA-free RNA was obtained using the RNeasy Mini Kit from QIAGEN 
with DNase treatment, and 0.5 μg of total RNA was reverse transcribed using a First Strand 
cDNA Synthesis kit (Fermentas, Hanover, MD). Real time PCR was performed in triplicate 
using the iCycler iQ thermal cycler and detection system (Applied Biosystems, Carlsbad, 
CA) following the manufacturer’s protocols. Expression of the tested gene was normalized 
relative to levels of GAPDH.
RNA-sequencing
Total RNA was first extracted using RNeasy mini kit (Qiagen). True-seq sample preparation 
kits (Illumina) were then used to purify poly-A transcripts and generate libraries with 
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multiplexed barcode adaptors. All samples passed quality control analysis on a Bioanalyzer 
2100 (Agilent). Paired-end reads (50 × 2 cycles, ~75×106 reads per sample) were obtained 
on an Illumina HiSeq 2500/1500 in the Weill Cornell Medical College Genomics Resources 
Core Facility. The TopHat program (v 1.2.0) was used to align the reads to the UCSC Hg19 
human reference genome, while the Cufflinks program (v. 0. 93) allowed for measurements 
of transcript abundance (represented by Fragments Per Kilobase of exon model per Million 
mapped reads (FPKM)). Genes and transcripts with FPKM values lower than five were not 
included in the analysis. Pearson correlation analysis and heatmaps was generated using R 
(3.0.2). The RNA sequencing data have been deposited to the Sequence Read Archive 
(http://www.ncbi.nlm.nih.gov/sra/) and assigned study number SRP047069.
Chromatin Immunoprecipitation (ChIP)
ChIP was performed as previously described 14. Briefly, 2 × 107 human primary OCPs were 
fixed by adding formaldehyde directly to the medium to a final concentration of 1 % for 5 
min. Cells were harvested, washed, and lysed. Chromatin was sheared by sonication to a 
length of approximately 500 base pairs using a Bioruptor sonicator (Diagenode). Sheared 
chromatin was precleared and then immunoprecipitated with antibodies; c-myc (Abcam; 
ab56), Brd4 (Bethyl Lab; A301-985A), pan acetyl-H4 (Millipore; 06-866), and CBP 
(Abcam; ab2832). Immune complexes were subsequently collected and washed, and DNA 
crosslinking was reversed by heating at 65°C overnight. Following proteinase K digestion, 
DNA was recovered using the PCR purification kit (Qiagen) and real time PCR was 
performed to detect the occupancy of target proteins. Signals obtained from the ChIP are 
divided by signals obtained from an input sample. This input sample represents the amount 
of chromatin used in the ChIP. The primer sequences are listed in Supplementary Table 3.
Statistical analysis
All statistical analyses were performed with Graphpad Prism 5.0 software using the 2-tailed, 
unpaired t-test (two conditions), one-way or two-way ANOVA for multiple comparisons 
(more than two conditions) with posthoc Tukey test. p<0.05 was taken as statistically 
significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. I-BET151 inhibits osteoclastogenesis
a. Human OCPs (CD14+ monocytes cultured overnight with M-CSF (20 ng ml−1)) were 
treated with DMSO (vehicle control, labeled 0) or I-BET151 at the indicated concentrations 
for 1hr prior to addition of RANKL (40 ng ml−1). After 5 days of culture, TRAP-positive, 
multinucleated (more than three nuclei) cells were counted in triplicate. The number of 
osteoclasts generated by RANKL alone is set as 100% for each individual blood donor. 
Upper panel, Representative results from one of more than three experiments. Lower panel, 
Data are shown as mean ± SEM from aggregate data from 9 independent donors. **: P < 
0.01, ***: P < 0.001 by two-way ANOVA. b. Human OCPs were cultured as in a for 5 days 
and mRNA was measured using real-time PCR. mRNA levels were normalized relative to 
GAPDH mRNA. Representative results from at least three independent experiments are 
shown. c–e. TNF-induced osteolysis model. TNF (70 μg per kg body weight) was injected 
over calvarial periosterium for four consecutive days, during which time either vehicle 
control or I-BET151 (40 mg kg −1 body weight) in 10 % KLEPTOSE® was administrated 
intraperitoneally (i.p.) once per day. Data shown are from 6 mice per group. c. TRAP 
staining of histological sections obtained from control or I-BET151 treated mice after 
supracalvarial TNF administration. Scale bar: 100 μm. d. ELISA measurement of serum 
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TRAP. *: P < 0.05 by one-way ANOVA. e. Histomorphometric analysis. Osteoclast number 
per bone surface (N.Oc BS−1). Osteoclast surface area per bone surface (OcS BS−1). All 
data are shown as mean ± SEM. *:P < 0.05 by t-test.
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Figure 2. I-BET 151 increases bone mass and strength in ovariectomized mice
a. A schematic diagram illustrating the therapeutic experimental design. b–c. Therapeutic 
effect of the BET bromodomain protein inhibitor, I-BET151 on post ovariectomy bone loss 
(n=12 per group). Sham-operated mice (Sham). b. Representative images showing 
trabecular architecture by micro-computed tomography (μCT) reconstruction in the distal 
femurs. Scale bars, 1 mm. c. μCT measurements for the indicated parameters in distal 
femurs. Bone volume (BV/TV), trabecular space (Tb.Sp.), trabecular number (Tb.N.) and 
trabecular thickness (Tb.Th.) were determined by μCT analysis. d. 3-point bending test of 
femurs. e. Histomorphometric analysis of tibia. Osteoclast number per bone surface (N.Oc 
BS−1). Osteoclast surface area per bone surface (OcS BS−1). All data are shown as mean ± 
SEM * P <0.05, ** P <0.01. One-way ANOVA with a posthoc Tukey test was performed.
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Figure 3. I-BET151 attenuates K/BxN serum–induced arthritis
Arthritis was induced in C57BL/6 mice and I-BET151 was administered as described in 
Methods. a. Time course of joint swelling in the presence and absence of I-BET151 
treatment. Values are the mean ± SEM of 6 mice per group. ***: P < 0.001 by two-way 
ANOVA. b. Histology of ankle joints of mice examined 11 days after the first arthritogenic 
serum injection. Hind paws were fixed and decalcified, and ankle joint sections were 
prepared and stained with hematoxylin, fast green, and Safranin O. Scale bar: 500μm c. 
Serum TRAP levels were measured 7 days after arthritis induction. *: P < 0.05 by two-way 
ANOVA. d. TRAP staining of histological sections obtained from control or I-BET151 
treated arthritic mice. Blue square (inset) shows an enlarged image. Scale bar:100μm e. 
Histomorphometric analysis. Osteoclast number per bone surface (N.Oc BS−1). Osteoclast 
surface area per bone surface (OcS BS−1). All data are shown as mean ± SEM. *:P < 0.05 
by t-test.
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Figure 4. I-BET151 inhibits NFATC1 expression
Human OCPs were treated with DMSO or I-BET151 for 1 hr, and then cultured with 
RANKL (40 ng ml−1) for one day. a. upper panel: Heat map of RNA-seq FPKM values for 
465 genes which were induced > 2-fold by RANKL and whose expression was suppressed 
by >50% by I-BET151 in two independent donors as shown Supplementary Fig. 8. Lower 
panel: box plot depicting FPKM values. (n=2) b. mRNA was measured using real-time PCR 
and normalized relative to GAPDH mRNA. Results are shown as means ± SD of triplicate 
determinants. c. Immunoblot of whole-cell lysates using NFATc1, Blimp1 and p38 
antibodies. Same samples were loaded into two gels and p38 was served as a loading control 
for each gel. Suppression of NFATc1 expression by I-BET151 was observed in at least 10 
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independent experiments. Images have been cropped for presentation; full size blots are 
shown in Supplementary Figure 18. d–f. Human OCPs were treated with DMSO (vehicle 
control) or I-BET151 (500 nM) for 1 hr, and RANKL (40ng ml−1) was added for additional 
24 hrs. Chromatin immunoprecipitation (ChIP) analysis of the NFATC1 promoter for Brd4 
(d), acetylated H4 (e), or CBP (f). All data are shown as mean ± SD. Representative results 
from at least three independent experiments are shown.
Park-Min et al. Page 19
Nat Commun. Author manuscript; available in PMC 2015 May 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5. I-BET151 suppresses RANKL-induced MYC expression
a. Human OCPs were treated with DMSO or I-BET151 at the indicated concentrations for 1 
hr, and then cultured with RANKL (40 ng ml−1) for one day (n=4). Analysis of expression 
of MYC mRNA by real time-PCR. All data are shown as mean ± SEM. ***:P < 0.001 by 
One-way ANOVA. b. (n=4) Osteoclastogenesis assay. Human OCPs were cultured with 
either DMSO (vehicle control) or 10058-F4 at the indicated doses for 1 hr prior to RANKL 
stimulation, and TRAP-positive multinucleated (more than three nuclei) cells were counted 
5 days after RANKL addition. Upper panel, Representative results obtained from one donor 
are shown. Lower panel, Data are shown as means ± SEM. c–d. Cells were cultured with 
10058-F4 at the indicated doses for 1hr, and RANKL was then added for 2 days. c. 
Immunoblot of whole cell lysates with NFATc1 and p38 antibodies. Images have been 
cropped for presentation; full size blots are shown in Supplementary Figure 18. d. NFATc1 
mRNA was measured by real-time PCR. mRNA levels were normalized to the expression of 
GAPDH. e–g. ChIP analysis for MYC (e), acetylated H4 (f), or CBP (g) at the NFATC1 
promoter in human OCPs. Representative results from three independent experiments are 
shown. All data are shown as mean ± SD. h. MYC and NFATC1 expression in RA synovial 
macrophages mRNA from synovial CD14+ cells from rheumatoid arthritis patients (n=16) 
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or sero-negative arthritis disease control patients (n=11) was measured using real-time PCR. 
mRNA levels were normalized relative to the expression of GAPDH. All data are shown as 
mean ± SEM.*: P < 0.05; by t-test. i–j. TNF-induced supracalvareal osteolysis. n=6. TNF 
(83 μg per kg body weight) was injected over calvarial periosterium for five consecutive 
days, and either vehicle (DMSO) or 10058-F4 (30 mg kg−1) was administrated 
intraperitoneally (i.p.) once per day. i. The concentration of serum TRAP measured by 
ELISA. j. Histomorphometric analysis of calvaria from either vehicle or 10058-F4 treated 
mice; osteoclast number per bone surface (N.Oc BS−1) and osteoclast surface area per bone 
surface (OcS BS−1). All data are shown as mean ± SEM. *:P < 0.05 by t-test.
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